Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

16.17 0.81

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.63

Max

16.26

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.4M

-14M

Pelnas, tenkantis vienai akcijai

-0.15

Darbuotojai

37

EBITDA

312K

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+96.52% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-71M

1.3B

Ankstesnė atidarymo kaina

15.36

Ankstesnė uždarymo kaina

16.17

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-08 23:56; UTC

Sirius XM Holdings Inc shares are higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month trading range.

2026-07-08 23:56; UTC

MercadoLibre Inc. shares declined during after-market hours, reflecting broader market sentiment amid rising oil prices and inflationary pressures from Middle East tensions.

2026-07-08 23:56; UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

2026-07-08 23:52; UTC

UK House Price Balance Declines to -0.33%, Heightening Concerns Over Housing Market Stability Amid Economic Pressures

2026-07-08 23:52; UTC

Positive Shift in U.S. Home Sales Anticipated as June Data Shows 5.9% Year-over-Year Increase Ahead of July Release.

2026-07-08 23:52; UTC

Optimism Grows Ahead of July 9 Release for U.S. Existing Home Sales Amid Lower Mortgage Rates and Increased Listings

2026-07-08 23:52; UTC

Australia's Westpac Consumer Confidence Index shows a 3.5% drop, signaling ongoing economic concerns ahead of July 14 release amid inflationary pressures and market volatility.

2026-07-08 23:52; UTC

Australia's Westpac Consumer Confidence Index set for July 14, 2026 release amid cautious investor sentiment and global economic pressures.

2026-07-08 23:51; UTC

Gilead Sciences shares are lower in after-hours trading, reflecting a decline from earlier levels amid broader market weakness influenced by geopolitical tensions.

2026-07-08 23:51; UTC

News

Broadcom shares rise in after-market hours as analysts project $172 billion in revenue next year, driven by AI infrastructure spending.

2026-07-08 23:51; UTC

U.S. equity markets show mixed results amid rising oil prices and geopolitical tensions, with European markets declining sharply as inflation fears grow.

2026-07-08 23:51; UTC

Geopolitical tensions and rising oil prices drive mixed Asian equity markets, with European indices declining amid inflation concerns and revised global growth forecasts.

2026-07-08 23:51; UTC

Global equity markets decline amid rising oil prices and geopolitical tensions, with U.S. consumer credit unexpectedly falling.

2026-07-08 23:51; UTC

European equity markets drop as DAX 30 falls 2.5% amid escalating Middle East tensions, rising oil prices, and inflation concerns.

2026-07-08 23:51; UTC

Macro News
ETF Constituents
Correlated Moves

Materials Select Sector SPDR Fund declines in after-market hours amid geopolitical tensions affecting global oil markets and related asset sentiment.

2026-07-08 23:51; UTC

News
Social Media

Costco Wholesale reported net sales of $29.24 billion for June but shares declined in after-hours trading amid mixed investor sentiment and broader market trends.

2026-07-08 23:51; UTC

Correlated Moves

The NZD/HKD is higher today, reflecting a modest increase since Tuesday's close, despite declines in European markets, including the DAX 30 Index.

2026-07-08 23:51; UTC

Correlated Moves
Macro News

The New Zealand Dollar has strengthened against major currencies after the Reserve Bank raised its key interest rate to 2.50%.

2026-07-08 23:51; UTC

Macro News
ETF Constituents

iShares MSCI South Korea ETF declines in after-market hours amid KOSPI's significant drop and rising global economic concerns linked to Middle East tensions.

2026-07-08 23:51; UTC

Macro News
ETF Constituents

The iShares U.S. Aerospace & Defense ETF declined in after-market trading amid rising tensions from U.S. military strikes against Iranian targets, impacting key defense firms.

2026-07-08 23:51; UTC

Correlated Moves
Macro News

Bitcoin is trading lower amid rising geopolitical tensions following President Trump's ceasefire announcement with Iran. Earlier, it reached a session high before declining.

2026-07-08 23:46; UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting routine trading activity with minimal fluctuations and positioning above the 20-day moving average.

2026-07-08 23:46; UTC

Fastenal Co shares are trading lower in after-market hours, marking the fifth consecutive day of declines amid broader market weakness linked to geopolitical tensions.

2026-07-08 23:46; UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite significant declines in European markets amid geopolitical tensions involving the U.S. and Iran.

2026-07-08 23:46; UTC

News
ETF Constituents
Macro News
Correlated Moves

The Financial Select Sector SPDR Fund is higher in after-market trading, supported by strong seasonal patterns and movements in major bank holdings.

2026-07-08 23:46; UTC

Western Digital shares are lower in after-market trading, amid broader market declines linked to geopolitical tensions affecting oil supply routes.

2026-07-08 23:41; UTC

News
Social Media
Correlated Moves

Advanced Micro Devices shares are declining in after-hours trading amid negative sentiment in semiconductor stocks, following the announcement of its upcoming earnings report.

2026-07-08 23:41; UTC

U.S. 30-Year Mortgage Rate Rises to 6.58%, Sparking Decline in Applications Amid Inflation and Economic Uncertainty

2026-07-08 23:41; UTC

Social Media
News

NVIDIA Corp shares declined in after-market trading amid concerns over AI spending and competition. Analysts note cautious investor sentiment contributing to the bearish outlook.

2026-07-08 23:41; UTC

News
Social Media
Correlated Moves

Micron Technology shares traded higher after notable options activity, with $7.2 million in orders for $815 7/17 Puts contributing to a total premium of over $21.5 million.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

96.52% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD  96.52%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat